Filtered By:
Management: Funding
Vaccination: Veterinary Vaccinations
This page shows you your search results in order of date.
Order by Relevance | Date
Total 34 results found since Jan 2013.
News at a glance: China ’s ethics oversight, ARPA-H’s new science, and $210 million for protein research
PUBLIC HEALTH
FDA advisers back maternal RSV shot
A vaccine aims to protect infants from respiratory syncytial virus, a leading cause of infant hospitalization.
JAMIE KELTER DAVIS/
THE NEW YORK TIMES
/REDUX
A panel advising the U.S. Food and Drug Administration (FDA) last week recommended that it approve a vaccine given to pregnant people to protect infants from respiratory syncytial virus (RSV), which can cause severe lung infections. The vote was unanimous based on the efficacy of the vaccine, called RSVpreF and branded Abrysvo. Ten members of the panel also...
Source: Science of Aging Knowledge Environment - May 25, 2023 Category: Geriatrics Source Type: research
A Look Back at 2022: Progress Towards the Treatment of Aging as a Medical Condition
At the end of 2022, we can reflect on the fact that we are steadily entering a new era of medicine, one in which mechanisms of aging are targeted rather than ignored. It is a profound change, one that will change the shape of a human life and ultimately the human condition by eliminating the greatest sources of suffering and death in the world. Year after year, we see increased funding, ongoing progress towards therapies capable of slowing aging or reversing aspects of aging, and a growing taxonomy of such potential therapies and their target mechanisms.
The view of aging in the medical community and public at large...
Source: Fight Aging! - December 30, 2022 Category: Research Authors: Reason Tags: Of Interest Source Type: blogs
U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
The Macro View – Health, Economics, and Politics and the Big Picture. What I Am Watching Here And Abroad.
August 18, 2022 Edition-----The main issue, probably of the year, is the increasing tension across the Taiwan Strait with all sorts of worries about how conflict can be avoided and prosperity maintained at a reasonable level as tensions continue. And hopefully ease.The impact of climate change in Europe is really becoming obvious and worrying. I am not sure just how a realistic response is possible in any reasonable time.In OZ the PM has come back after a week off to have the Chinese Ambassador tell us we are a vassal and to just shut up and behave. Astonishing and serious stuff IMVHO.-----Major Issues.-----https://www.smh...
Source: Australian Health Information Technology - August 18, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
NIDCR's Spring 2022 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Spring 2022 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities & Related Notices
NIH/HHS News
Subscribe to NIDCR News
Science Advances
NIDCR News
NIH & NIDCR Release “Oral Health in America: Advances and Challenges”
In December, NIDCR announced the release of a report that provides a comprehensive snapshot of oral health in America, detailing 20 years of advances and challenges and drawing on data from public research and evidence-based practices. For more ...
Source: NIDCR Science News - March 3, 2022 Category: Dentistry Source Type: news
Fight Aging! Newsletter, January 11th 2021
This study demonstrates the potential of a natural (o-Vanillin) and a synthetic (RG-7112) senolytic compounds to remove senescent IVD cells, decrease SASP factors release, reduce the inflammatory environment and enhance the IVD matrix production. Removal of senescent cells, using senolytics drugs, could lead to improved therapeutic interventions and ultimately decrease pain and a provide a better quality of life of patients living with intervertebral disc degeneration and low back pain.
From Ying Ann Chiao of Oklahoma Medical Research Foundation: Mitochondrial dysfunction plays a central role in aging and cardiovasc...
Source: Fight Aging! - January 10, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Fight Aging! Newsletter, October 5th 2020
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter,
please visit:
https://www.fightaging.org/newsletter/
Longevity Industry Consulting Services
Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - October 4, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
NIDCR's Fall 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Fall 2020 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities
NIH/HHS News
Funding Notices
Science Advances
Subscribe to NICDR News
Grantee News
NIDCR News
NIDCR Announces Availability of COVID-19 Research Funding
On May 5, NIDCR issued two Notices of Special Interest highlighting the urgent need for research on coronavirus disease 2019. This research may be conducted either via the National Dental PBRN infrastructure or inde...
Source: NIDCR Science News - September 1, 2020 Category: Dentistry Source Type: news
Fight Aging! Newsletter, August 24th 2020
We report that electrical stimulation (ES) stimulation of post-stroke aged rats led to an improved functional recovery of spatial long-term memory (T-maze), but not on the rotating pole or the inclined plane, both tests requiring complex sensorimotor skills. Surprisingly, ES had a detrimental effect on the asymmetric sensorimotor deficit.
Histologically, there was a robust increase in the number of doublecortin-positive cells in the dentate gyrus and SVZ of the infarcted hemisphere and the presence of a considerable number of neurons expressing tubulin beta III in the infarcted area. Among the genes that were unique...
Source: Fight Aging! - August 23, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
NIDCR's Summer 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Summer 2020 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities
NIH/HHS News
Funding Notices
Science Advances
Subscribe to NICDR News
Grantee News
NIDCR News
NIDCR Announces Availability of COVID-19 Research Funding
On May 5, NIDCR issued two Notices of Special Interest highlighting the urgent need for research on coronavirus disease 2019. This research may be conducted either via the National Dental PBRN infrastructure or in...
Source: NIDCR Science News - June 4, 2020 Category: Dentistry Source Type: news
Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19.
It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Fight Aging! Newsletter, August 12th 2019
We examined 9293 individuals from the Copenhagen General Population Study using nuclear magnetic resonance spectroscopy measurements of total cholesterol, free- and esterified cholesterol, triglycerides, phospholipids, and particle concentration. Fourteen subclasses of decreasing size and their lipid constituents were analysed: six subclasses were very low-density lipoprotein (VLDL), one intermediate-density lipoprotein (IDL), three low-density lipoprotein (LDL), and four subclasses were high-density lipoprotein (HDL). Remnant lipoproteins were VLDL and IDL combined.
Mean nonfasting cholesterol concentration was 72...
Source: Fight Aging! - August 11, 2019 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Fight Aging! Newsletter, July 22nd 2019
This study elucidates the potential to use mitochondria from different donors (PAMM) to treat UVR stress and possibly other types of damage or metabolic malfunctions in cells, resulting in not only in-vitro but also ex-vivo applications.
Gene Therapy in Mice Alters the Balance of Macrophage Phenotypes to Slow Atherosclerosis Progression
https://www.fightaging.org/archives/2019/07/gene-therapy-in-mice-alters-the-balance-of-macrophage-phenotypes-to-slow-atherosclerosis-progression/
Atherosclerosis causes a sizable fraction of all deaths in our species. It is the generation of fatty deposits in blood vessel...
Source: Fight Aging! - July 21, 2019 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Gene Therapy Leaves a Vicious Cycle
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4*
1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States
2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States
3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - April 23, 2019 Category: Cancer & Oncology Source Type: research
